{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:16:43Z","timestamp":1771460203971,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","annalspathology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.anndiagpath.2015.07.008","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T19:20:18Z","timestamp":1438456818000},"page":"418-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["HPV vaccines: their pathology-based discovery, benefits, and adverse effects"],"prefix":"10.1016","volume":"19","author":[{"given":"Alcina F.","family":"Nicol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia V.","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio B.","family":"Russomano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana S.L.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalia S.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"David William","family":"Provance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard J.","family":"Nuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0005","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.vaccine.2015.01.084","article-title":"Reduction in HPV 16\/18-associated high grade cervical lesions following HPV vaccine introduction in the United States\u20142008-2012","volume":"33","author":"Hariri","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0010","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0020","first-page":"685","article-title":"National and state vaccination coverage among adolescents aged 13-17 years\u2014United States (2012)","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0025","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0030","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(13)61831-0","article-title":"HPV vaccination programme in Japan","volume":"382","author":"Gilmour","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0035","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"Br Med J"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0040","series-title":"Genital papillomaviruses and related neoplasms","author":"Crum","year":"1999"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0045","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.1990.03440090057026","article-title":"Human papillomavirus types and recurrent genital warts","volume":"263","author":"Nuovo","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0050","first-page":"632","article-title":"Human papillomavirus types and recurrent cervical warts in immunocompromised women","volume":"4","author":"Nuovo","year":"1991","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0055","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0060","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0065","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40265-014-0255-z","article-title":"Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0070","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.2014.2198","article-title":"Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism","volume":"312","author":"Scheller","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0085","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jpeds.2014.02.043","article-title":"No association of HPV vaccination with serious adverse events","volume":"164","author":"Caskey","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.02.043","article-title":"Human papillomavirus vaccine and systemic lupus erythematosus","author":"Gatto","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trivac.2013.08.001","article-title":"Implementation of the quadrivalent vaccine against HPV in the Municipality of Campos dos Goytacazes, Brazil\u2014a combination of strategies to increase immunization coverage and early reduction of genital warts","author":"Kury","year":"2013","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0100","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ramb.2013.03.004","article-title":"Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region","volume":"59","author":"Fonseca","year":"2013","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0105","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ijc.28431","article-title":"Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men","volume":"134","author":"Berry","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0110","doi-asserted-by":"crossref","first-page":"e102676","DOI":"10.1371\/journal.pone.0102676","article-title":"HIV-1, HBV, HCV, HTLV, HPV-16\/18, and Treponema pallidum infections in a sample of Brazilian men who have sex with men","volume":"9","author":"Soares","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.anndiagpath.2015.07.008_bb0115","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.vaccine.2014.10.052","article-title":"Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirusvaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia","volume":"32","author":"Deshmuk","year":"2014","journal-title":"Vaccine"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913415001197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913415001197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T20:29:30Z","timestamp":1567024170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913415001197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1092913415001197"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2015.07.008","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPV vaccines: their pathology-based discovery, benefits, and adverse effects","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2015.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}